AstraZeneca to repurchase $4bn of stock

first_img More From Our Partners Supermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Share AstraZeneca to repurchase $4bn of stock KCS-content whatsapp Tags: NULL whatsappcenter_img by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastSerendipity TimesInside Coco Chanel’s Eerily Abandoned Mansion Frozen In TimeSerendipity TimesBrake For ItThe Most Worthless Cars Ever MadeBrake For ItBetterBe20 Stunning Female AthletesBetterBeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryLuxury SUVs | Search AdsThese Cars Are So Loaded It’s Hard to Believe They’re So CheapLuxury SUVs | Search AdsAlphaCute30 Rules That All “Hells Angels” Have To FollowAlphaCuteDefinitionDesi Arnaz Kept This Hidden Throughout The Filming of ‘I Love Lucy’DefinitionTaonga: The Island FarmThe Most Relaxing Farm Game of 2021. No InstallTaonga: The Island Farm ASTRAZENECA beat forecasts for the fourth quarter yesterday, reporting a two per cent rise in pre-tax profits for 2010, up to $10.98bn (£6.89bn) from $10.8bn in 2009.The UK’s second largest drug-maker saw earnings buoyed by strong sales in key products such as Crestor, an anti-cholesterol treatment.And the report cheered investors with a promise to double its share buyback programme to $4bn.“Despite government pricing pressures and anticipated patent expiries in the US and western Europe, our revenues remained in line with the previous year,” said chief executive David Brennan.The performance was attributed to brands and continued growth in emerging markets. Sales in emerging markets exceeded $5bn for the first time, the drug firm added.The company’s final year results set a target for core earnings per share between the range of $6.45 to $6.75.Earnings per share for the fourth quarter reached $1.39, above consensus forecasts of $1.35, as sales for the three months to December hit $8.617bn, above consensus forecasts of $8.385bn. Show Comments ▼ Thursday 27 January 2011 8:45 pmlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *